HHV8
MCID: KPS004
MIFTS: 75

Kaposi Sarcoma (HHV8)

Categories: Blood diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Kaposi Sarcoma

MalaCards integrated aliases for Kaposi Sarcoma:

Name: Kaposi Sarcoma 56 12 74 52 58 36 54 42 15 71 32
Kaposi Sarcoma, Susceptibility to 56 29 13 6
Kaposi's Sarcoma 12 52 15 17
Angiofollicular Ganglionic Hyperplasia 58 71
Kaposi's Sarcoma of Soft Tissue 12 71
Kaposi's Sarcoma of Palate 12 71
Kaposi's Sarcoma of Lung 12 71
Multiple Idiopathic Pigmented Hemangiosarcoma, Susceptibility to 56
Multiple Idiopathic Pigmented Hemangiosarcoma 56
Kaposi's Sarcoma of Central Nervous System 12
Kaposi's Sarcoma of Gastrointestinal Sites 12
African Lymphadenopathic Kaposi's Sarcoma 12
Central Nervous System Kaposi's Sarcoma 12
Kaposi's Sarcoma-Associated Herpesvirus 12
Kaposi's Sarcoma of the Gallbladder 12
Sarcoma, Kaposi, Susceptibility to 39
Angiofollicular Lymph Hyperplasia 58
Lymphadenopathic Kaposi's Sarcoma 12
Multi-Centric Castleman's Disease 71
Kaposi's Sarcoma of Soft Tissues 12
Kaposi's Sarcoma of the Prostate 12
Kaposi's Sarcoma of Conjunctiva 12
Kaposi's Sarcoma of Lymph Nodes 12
Non Aids Related Kaposi Sarcoma 52
Non-Aids-Related Kaposi Sarcoma 71
Conjunctival Kaposi's Sarcoma 12
Kaposi's Sarcoma of Esophagus 12
Gallbladder Kaposi's Sarcoma 12
Soft Tissue Kaposi's Sarcoma 12
Mediterranean Kaposi Sarcoma 52
Esophageal Kaposi's Sarcoma 12
Intestinal Kaposi's Sarcoma 12
Kaposi's Sarcoma of the Cns 12
Lymph Node Kaposi's Sarcoma 12
Cutaneous Kaposi's Sarcoma 12
Kaposi's Sarcoma of Cornea 12
Pulmonary Kaposi's Sarcoma 12
Kaposi Sarcoma Herpesvirus 52
Kaposi's Sarcoma of Heart 12
Kaposi's Sarcoma of Penis 12
Prostate Kaposi's Sarcoma 12
Angiolymphoid Hyperplasia 71
Cardiac Kaposi's Sarcoma 12
Corneal Kaposi's Sarcoma 12
Gastric Kaposi's Sarcoma 12
Kaposi's Sarcoma of Anus 12
Kaposi's Sarcoma of Skin 12
Palate Kaposi's Sarcoma 12
Kaposi's Sarcoma, Lung 12
Kaposi's Sarcoma, Skin 12
Penis Kaposi's Sarcoma 12
Anal Kaposi's Sarcoma 12
Human Herpesvirus 8 52
Castleman Disease 58
Sarcoma, Kaposi 43
Hhv8 52
Kshv 52

Characteristics:

Orphanet epidemiological data:

58
kaposi sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult;
castleman disease
Inheritance: Not applicable; Age of onset: All ages;

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
kaposi sarcoma:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare circulatory system diseases
Developmental anomalies during embryogenesis
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:8632
OMIM 56 148000
KEGG 36 H00041
MeSH 43 D012514
SNOMED-CT 67 49937004
MESH via Orphanet 44 C536362 D005871 D012514
UMLS via Orphanet 72 C0017531 C0036220 C2931179
MedGen 41 C3538945
UMLS 71 C0017531 C0036220 C0153560 more

Summaries for Kaposi Sarcoma

NIH Rare Diseases : 52 Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body (including the lymph nodes , lungs, or digestive tract). The abnormal cells of Kaposi sarcoma cause purplish, reddish blue, or dark brown/black skin lesions (macules , nodules , plaques) on the legs and the face. These lesions may look bad, but they usually cause no symptoms. However, when the lesions are in the lungs, liver, or digestive tract, they may cause serious problems like gastrointestinal bleeding or trouble breathing. Kaposi sarcoma is caused by infection with a virus called the Kaposi sarcoma associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8). Kaposi sarcoma is classified into four types based upon the different populations in which it develops: classic (which presents in middle or old age), endemic (described in sub-Saharan indigenous Africans), iatrogenic (associated with immunosuppressive drug therapy) and AIDS-associated (epidemic KS). Options for treatment may include local therapy , radiation therapy , chemotherapy and biologic therapy (immunotherapy ). The main aim is to restore immunity.

MalaCards based summary : Kaposi Sarcoma, also known as kaposi sarcoma, susceptibility to, is related to human herpesvirus 8 and glomeruloid hemangioma, and has symptoms including fever, pruritus and exanthema. An important gene associated with Kaposi Sarcoma is IL6 (Interleukin 6), and among its related pathways/superpathways are Kaposi sarcoma-associated herpesvirus infection and Viral carcinogenesis. The drugs Lopinavir and Stavudine have been mentioned in the context of this disorder. Affiliated tissues include skin, endothelial and lymph node, and related phenotypes are recurrent herpes and hypermelanotic macule

Disease Ontology : 12 A connective tissue cancer that derives from lymphatic endothelium, and derives from spindle cells, results in formation of vascular channels that fill with blood cells, has material basis in Human herpesvirus 8 (HHV8).

OMIM : 56 Kaposi sarcoma (KS) is an invasive angioproliferative inflammatory condition that occurs commonly in men infected with human immunodeficiency virus (HIV; see 609423). In the early stages of KS, lesions appear reactive and are stimulated to grow by the actions of inflammatory cytokines and growth factors. In the late stages of KS, a malignant phenotype that appears to be monoclonal can develop. Infection with human herpesvirus-8 (HHV-8), also known as KS-associated herpesvirus (KSHV), is necessary but not sufficient for KS development. Coinfection with HIV markedly increases the likelihood of KS development, and additional environmental, hormonal, and genetic cofactors likely contribute to its pathogenesis (summary by Foster et al., 2000). Suthaus et al. (2012) noted that HHV-8 is the etiologic agent not only of KS, but also of primary effusion lymphoma and plasma cell-type multicentric Castleman disease (MCD). (148000)

MedlinePlus : 42 Kaposi sarcoma (KS) is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, in lymph nodes, or in other organs. These patches, or lesions, are usually red or purple. They are made of cancer cells, blood vessels, and blood cells. KS is caused by infection with human herpesvirus-8 (HHV-8). Most people infected with HHV-8 don't get KS. It usually happens in People with weak immune systems, due to HIV/AIDS, drugs taken after an organ transplant, or another disease Older men of Jewish or Mediterranean descent Young men in Africa The skin lesions may not cause symptoms. But they can spread to other parts of the body, especially in people with HIV/AIDS. If they spread to the digestive tract or lungs, they can cause bleeding. Lesions on the lungs can also make it hard to breathe. Treatment depends on where the lesions are and how bad they are. Options include radiation therapy, surgery, chemotherapy, and biologic therapy. People with HIV/AIDS also take HIV/AIDS medicines. NIH: National Cancer Institute

KEGG : 36 Kaposi sarcoma (KS) is an angioproliferative disease classified into classic KS, endemic KS, iatrogenic KS, and HIV-associated KS (HIV-KS), however, share the same histological traits and are all associated with infection by the human herpesvirus 8 (HHV8; also known as KSHV). Evidence indicates that KS progression occurs upon the deregulated expression of anti-apoptotic genes (Bcl-2), oncogenes (c-myc, c-int, ras) and oncosuppressor genes (TP53), and is associated with the long-lasting expression of HHV8 latency genes (LANA, v-cyc D, v-FLIP, Kaposin). All these genes are, in fact, expressed or altered in most KS spindle cells in the nodular-late stage of KS. Bcl-2 acts as a major KS progression factor, and TP53 and c-myc may also have a role in disease progression. HHV8 latency gene products may be involved in KS progression due to their capability of promoting cell growth by direct effects or antiapoptotic effects.

Wikipedia : 74 Kaposi's sarcoma (KS) is a type of cancer that can form masses in the skin, lymph nodes, or other... more...

Related Diseases for Kaposi Sarcoma

Diseases related to Kaposi Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 951)
# Related Disease Score Top Affiliating Genes
1 human herpesvirus 8 34.5 IL6ST IL6 IFNA1
2 glomeruloid hemangioma 33.0 VEGFA IL6
3 acquired immunodeficiency syndrome 32.3 TP53 IL6 IFNA2 IFNA1 ICAM1
4 castleman disease 32.1 VEGFA IL6ST IL6 IFNA1 ICAM1
5 angiosarcoma 31.7 VEGFA TP53 KDR
6 lymphangioma 31.6 VEGFA KDR IFNA2
7 basal cell carcinoma 31.3 VEGFA TP53 IL6 ICAM1 FGF2
8 sarcoma 31.2 VEGFA TP53 PDGFB KDR IL6ST IL6
9 exanthem 31.2 VEGFA KDR IL6
10 intussusception 31.2 VEGFA KDR IL6 FGF2
11 human immunodeficiency virus type 1 31.1 IRF3 IL6 IFNA1 CXCL1 CASP8
12 plasma cell neoplasm 31.1 VEGFA TP53 IL6
13 pericardial effusion 31.1 VEGFA IL6 FGF2
14 cavernous hemangioma 31.0 VEGFA KDR FGF2
15 pleural disease 31.0 VEGFA TP53 IL6
16 varicose veins 31.0 VEGFA KDR IL6 ICAM1 FGF2
17 mantle cell lymphoma 31.0 VEGFA TP53 IL6 CDK6
18 hemangioma 31.0 VEGFA TP53 PDGFB KDR IFNA2 FGF2
19 splenomegaly 31.0 IFNA2 IFNA1 ADA2
20 relapsing-remitting multiple sclerosis 31.0 IL6 IFNB1 IFNA1 ICAM1
21 lymphoma, non-hodgkin, familial 30.9 VEGFA TP53 IL6 CDK6 CASP8
22 vascular cancer 30.9 VEGFA TP53 KDR IFNA2 FGF2
23 proctitis 30.9 VEGFA KDR FGF2
24 capillary hemangioma 30.9 VEGFA KDR FGF2
25 esophagitis 30.9 VEGFA TP53 IL6
26 vaccinia 30.9 TP53 IRF3 IL6 IFNB1 IFNA1 ICAM1
27 hepatitis b 30.8 TP53 IL6 IFNB1 IFNA2 IFNA1
28 primary cutaneous b-cell lymphoma 30.8 VEGFA KDR IFNA2
29 arteriovenous malformations of the brain 30.8 VEGFA KDR IL6
30 gastric ulcer 30.8 VEGFA IL6 FGF2
31 osteosclerotic myeloma 30.8 VEGFA IL6
32 arthritis 30.8 VEGFA IL6ST IL6 ICAM1 CXCL1
33 thrombocytopenia 30.8 IL6 IFNB1 IFNA2 IFNA1 ICAM1
34 gingivitis 30.8 VEGFA IL6 ICAM1
35 cryoglobulinemia 30.8 IL6 IFNA2 IFNA1
36 neovascular glaucoma 30.8 VEGFA KDR FGF2
37 lichen planus 30.6 TP53 IL6 ICAM1
38 retinal vascular disease 30.6 VEGFA KDR IL6 ICAM1 FGF2
39 aplastic anemia 30.6 VEGFA TP53 IL6 IFNA1 FGF2
40 burkitt lymphoma 30.6 TP53 IL6 IFNA1 ICAM1 CDK6 CASP8
41 macular retinal edema 30.6 VEGFA KDR IL6 IFNB1 ICAM1
42 myelofibrosis 30.6 VEGFA TP53 IFNA2 IFNA1 FGF2
43 plasmacytoma 30.5 VEGFA IL6ST IL6
44 myeloma, multiple 30.5 VEGFA TP53 KDR IL6 IFNA1 ICAM1
45 keratitis, hereditary 30.5 VEGFA IL6 FGF2 CXCL1
46 vasculitis 30.5 IL6 IFNA2 ICAM1 ADA2
47 viral infectious disease 30.5 IRF3 IL6 IFNB1 IFNA2 IFNA1 ICAM1
48 cystitis 30.5 VEGFA TP53 IL6 ICAM1 CXCL1
49 retinal detachment 30.5 VEGFA PDGFB IL6 FGF2
50 inflammatory bowel disease 30.4 VEGFA TP53 IL6ST IL6 ICAM1 FGF2

Graphical network of the top 20 diseases related to Kaposi Sarcoma:



Diseases related to Kaposi Sarcoma

Symptoms & Phenotypes for Kaposi Sarcoma

Human phenotypes related to Kaposi Sarcoma:

58 31 (show top 50) (show all 53)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 recurrent herpes 58 31 obligate (100%) Obligate (100%) HP:0005353
2 hypermelanotic macule 58 31 hallmark (90%) Very frequent (99-80%) HP:0001034
3 neoplasm of the skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0008069
4 abnormality of the lower limb 58 31 hallmark (90%) Very frequent (99-80%) HP:0002814
5 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
6 papule 58 31 frequent (33%) Frequent (79-30%) HP:0200034
7 abnormality of the spleen 58 31 frequent (33%) Frequent (79-30%) HP:0001743
8 hemangioma 58 31 frequent (33%) Frequent (79-30%) HP:0001028
9 lymphoproliferative disorder 58 31 frequent (33%) Frequent (79-30%) HP:0005523
10 abnormality of the gastrointestinal tract 58 31 frequent (33%) Occasional (29-5%),Frequent (79-30%) HP:0011024
11 encephalopathy 58 31 frequent (33%) Frequent (79-30%) HP:0001298
12 abnormal retinal morphology 58 31 frequent (33%) Frequent (79-30%) HP:0000479
13 skin nodule 58 31 frequent (33%) Frequent (79-30%) HP:0200036
14 generalized lymphadenopathy 58 31 frequent (33%) Occasional (29-5%),Frequent (79-30%) HP:0008940
15 fatigue 58 31 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0012378
16 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
17 skin rash 58 31 occasional (7.5%) Occasional (29-5%) HP:0000988
18 weight loss 58 31 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0001824
19 lymphedema 58 31 occasional (7.5%) Occasional (29-5%) HP:0001004
20 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
21 abnormal lung morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0002088
22 venous insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0005293
23 abnormality of the liver 58 31 occasional (7.5%) Occasional (29-5%) HP:0001392
24 skin plaque 58 31 occasional (7.5%) Occasional (29-5%) HP:0200035
25 nausea and vomiting 58 Occasional (29-5%)
26 renal insufficiency 58 Very rare (<4-1%)
27 dyspnea 58 Very rare (<4-1%)
28 anemia 58 Frequent (79-30%)
29 abdominal pain 58 Frequent (79-30%)
30 edema 31 HP:0000969
31 macule 58 Very frequent (99-80%)
32 hematuria 58 Very rare (<4-1%)
33 cough 58 Occasional (29-5%)
34 thrombocytopenia 58 Very rare (<4-1%)
35 jaundice 58 Occasional (29-5%)
36 intestinal obstruction 58 Very rare (<4-1%)
37 sarcoma 31 HP:0100242
38 mediastinal lymphadenopathy 58 Frequent (79-30%)
39 elevated c-reactive protein level 58 Frequent (79-30%)
40 lymphadenopathy 58 Very frequent (99-80%)
41 abdominal distention 58 Occasional (29-5%)
42 abdominal mass 58 Occasional (29-5%)
43 elevated erythrocyte sedimentation rate 58 Frequent (79-30%)
44 anasarca 58 Very rare (<4-1%)
45 constitutional symptom 58 Frequent (79-30%)
46 restrictive cardiomyopathy 58 Very rare (<4-1%)
47 follicular hyperplasia 58 Frequent (79-30%)
48 myelofibrosis 58 Very rare (<4-1%)
49 decreased mean corpuscular volume 58 Occasional (29-5%)
50 increased serum interleukin-6 58 Frequent (79-30%)

Symptoms via clinical synopsis from OMIM:

56
Oncology:
kaposi sarcoma

Misc:
rarely familial

Skin:
red-purple nodules, plaques, and macules
limb edema

Clinical features from OMIM:

148000

UMLS symptoms related to Kaposi Sarcoma:


fever, pruritus, exanthema

MGI Mouse Phenotypes related to Kaposi Sarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 CASP8 CDK6 FGF2 ICAM1 IFNB1 IL6
2 cellular MP:0005384 10.2 CASP8 CDK6 FGF2 FGF4 ICAM1 IL6
3 cardiovascular system MP:0005385 10.18 CASP8 CDK6 FGF2 ICAM1 IL6 IL6ST
4 immune system MP:0005387 10.18 CASP8 CCR8 CDK6 ICAM1 IFNB1 IL6
5 liver/biliary system MP:0005370 9.97 CASP8 CDK6 IL6 IL6ST KDR PDGFB
6 muscle MP:0005369 9.97 CASP8 CDK6 FGF2 ICAM1 IL6 KDR
7 neoplasm MP:0002006 9.91 CASP8 CDK6 FGF2 ICAM1 IFNB1 IL6
8 nervous system MP:0003631 9.9 CASP8 CDK6 FGF2 ICAM1 IFNB1 IL6
9 respiratory system MP:0005388 9.56 CASP8 FGF4 IL6 IRF3 KDR PDGFB
10 vision/eye MP:0005391 9.28 CDK6 FGF2 ICAM1 IL6 IL6ST KDR

Drugs & Therapeutics for Kaposi Sarcoma

Drugs for Kaposi Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 239)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lopinavir Approved Phase 4 192725-17-0 92727
2
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
3
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
4
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
5
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
6
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
7
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
8
Dolutegravir Approved Phase 4 1051375-16-6 54726191
9
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
10 Calcineurin Inhibitors Phase 4
11
protease inhibitors Phase 4
12 HIV Protease Inhibitors Phase 4
13 Cytochrome P-450 CYP3A Inhibitors Phase 4
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Anti-Retroviral Agents Phase 4
16 Anti-HIV Agents Phase 4
17 HIV Integrase Inhibitors Phase 4
18 Integrase Inhibitors Phase 4
19
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 5281106 54677470
20
Daunorubicin Approved Phase 3 20830-81-3 30323
21
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
22
Nicotine Approved Phase 3 54-11-5 942 89594
23
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 65140 441300
24
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
25
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
26
Varenicline Approved, Investigational Phase 3 249296-44-4 5310966
27
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
28
Etoposide Approved Phase 3 33419-42-0 36462
29
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
30
Efavirenz Approved, Investigational Phase 3 154598-52-4 64139
31
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
32
Nevirapine Approved Phase 3 129618-40-2 4463
33 Anti-Inflammatory Agents, Non-Steroidal Phase 3
34 Cyclooxygenase 2 Inhibitors Phase 3
35 Cyclooxygenase Inhibitors Phase 3
36 Antiparasitic Agents Phase 3
37 Antiprotozoal Agents Phase 3
38 Central Nervous System Stimulants Phase 3
39 Nicotinic Agonists Phase 3
40 Dideoxynucleosides Phase 2, Phase 3
41 Steroid Synthesis Inhibitors Phase 3
42 Liposomal amphotericin B Phase 3
43 Sunflower Phase 3
44 Antitubercular Agents Phase 3
45 Topoisomerase Inhibitors Phase 3
46 Reverse Transcriptase Inhibitors Phase 3
47 Anti-Bacterial Agents Phase 3
48 Antibiotics, Antitubercular Phase 3
49 Antimitotic Agents Phase 3
50 Etoposide phosphate Phase 3

Interventional clinical trials:

(show top 50) (show all 217)
# Name Status NCT ID Phase Drugs
1 A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
2 A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
3 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
4 Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial Recruiting NCT04077515 Phase 4 Sirolimus(0.8mg/m2);Sirolimus(0.7mg/m2)
5 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Not yet recruiting NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
6 Clinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to Valganciclovir Withdrawn NCT00361933 Phase 4 Valganciclovir
7 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
8 A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
9 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
10 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed NCT00002093 Phase 3 Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
11 Open Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
12 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate
13 Double-Blind Randomized Evaluation of Clinical Benefits of DOXIL in Patients With AIDS-Related Kaposi's Sarcoma Treated With DOXIL or DaunoXome Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
14 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
15 A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma Completed NCT00002445 Phase 3 IM862
16 A Placebo-Controlled Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT00000994 Phase 3 Zidovudine
17 Phase III Study of Paclitaxel Versus Liposomal Doxorubicin for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
18 A Randomized Evaluation of Antiretroviral Therapy Alone or With Delayed Chemotherapy Versus Antiretroviral Therapy With Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) AMC 067 Completed NCT01352117 Phase 3 efavirenz/emtricitabine/tenofovir disoproxil fumarate;etoposide
19 Comparison of Fluconazole (UK-49,858) and Amphotericin B for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00001017 Phase 3 Fluconazole;Amphotericin B
20 Preventing Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone Completed NCT01924286 Phase 3 Prednisone;Placebo
21 A Placebo Controlled Trial of Varenicline for Smoking Among Those With HIV/AIDS Completed NCT01710137 Phase 3 Varenicline;Placebo
22 Randomized Trial to Evaluate Mirasol Whole Blood Pathogen Reduction Technology System to Reduce Malaria and Emerging Transfusion Transmitted Infections Recruiting NCT03737669 Phase 3
23 A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis Recruiting NCT03092817 Phase 3 Dexamethasone
24 A Randomized Comparison of Three Regimens of Chemotherapy With Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings Active, not recruiting NCT01435018 Phase 3 Etoposide (ET);Bleomycin and Vincristine (BV);Paclitaxel (PTX);Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
25 Treatment of HIV-Related Kaposi's Sarcoma and Stage I-III Slow-Proliferative Disease With Highly Active Antiretroviral Therapy (HAART) Unknown status NCT00003419 Phase 2
26 Electrosclerotherapy as a Novel Treatment Option for Capillary Malformations: A Pilot Study Unknown status NCT02883023 Phase 2 Intralesional bleomycin injection
27 A Phase II Safety and Activity Study of Ritonavir in the Treatment of HIV-Associated Cutaneous Kaposi's Sarcoma Completed NCT00002366 Phase 2 Ritonavir
28 Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging. Completed NCT02201420 Phase 2 Tc 99m tilmanocept
29 PHASE II PROTOCOL WITH LABORATORY CORRELATES OF 1-[(S)-3-HYDROXY-2-(PHOSPHOMETHOXY)PROPYL]CYTOSINE DIHYDRATE(CIDOFOVIR) IN PATIENTS WITH KAPOSI'S SARCOMA (KS) Completed NCT00019240 Phase 2 cidofovir
30 Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma Completed NCT00002259 Phase 2 Mitoxantrone hydrochloride
31 Phase I/II Pilot Study of Interleukin-12 in Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT00019188 Phase 1, Phase 2 interleukin-12
32 A Phase II Trial of Topical Halofuginone in Patients With HIV Related Kaposi's Sarcoma Completed NCT00064142 Phase 2 halofuginone hydrobromide
33 An Open-Label Pilot Phase 2 Study to Investigate Efficacy, Safety, and Intratumoral Kinetics of ALDOXORUBICIN in HIV-Infected Patients With Kaposi's Sarcoma Completed NCT02029430 Phase 2 aldoxorubicin
34 A Phase II Study of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV-Related Kaposi's Sarcoma Completed NCT00002314 Phase 2 Ro 24-7429
35 Phase II Evaluation of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002212 Phase 2 Bexarotene
36 A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma Completed NCT00002131 Phase 2 Vesnarinone
37 A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Therapy-Refractory Cutaneous AIDS-Related Kaposi's Sarcoma Completed NCT00005931 Phase 2 SU5416
38 Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals Completed NCT00002189 Phase 2 Paclitaxel
39 Phase II Evaluation of Oral ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma. Completed NCT00002188 Phase 2 Alitretinoin
40 A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma Completed NCT00005042 Phase 2 semaxanib
41 Treatment of Classical Kaposi Sarcoma With Nicotine Dermal Patch: A Phase II Trial Completed NCT00295984 Phase 2 nicotine
42 Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. Completed NCT00002167 Phase 2 Tin ethyl etiopurpurin
43 A Phase II Trial Of Imatinib Mesylate (Gleevec) In Patients With HIV Related Kaposi's Sarcoma Completed NCT00090987 Phase 2 imatinib mesylate
44 A Phase II Trial With the HIV Protease Inhibitor Indinavir for the Treatment of Classical Kaposi's Sarcoma Completed NCT00362310 Phase 2 indinavir
45 A PHASE II STUDY OF ORAL THALIDOMIDE FOR PATIENTS WITH HIV INFECTION AND KAPOSI'S SARCOMA Completed NCT00019123 Phase 2 thalidomide
46 A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's Sarcoma Completed NCT00024024 Phase 1, Phase 2 rebimastat
47 Pilot Study to Evaluate the Potential Interactions Between Paclitaxel and Protease Inhibitors in Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00003008 Phase 2 indinavir sulfate;nelfinavir mesylate;paclitaxel;ritonavir;saquinavir mesylate
48 Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy Completed NCT00000807 Phase 2 Etoposide
49 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity Completed NCT01296815 Phase 2 Bevacizumab
50 Phase II Study of Weekly Doxorubicin Treatment of AIDS Associated Kaposi's Sarcoma Completed NCT00000996 Phase 2 Doxorubicin hydrochloride

Search NIH Clinical Center for Kaposi Sarcoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alitretinoin
doxorubicin hydrochloride liposome
Etoposide
etoposide phosphate
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Paclitaxel
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
siltuximab
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: sarcoma, kaposi

Genetic Tests for Kaposi Sarcoma

Genetic tests related to Kaposi Sarcoma:

# Genetic test Affiliating Genes
1 Kaposi Sarcoma, Susceptibility to 29 IL6

Anatomical Context for Kaposi Sarcoma

MalaCards organs/tissues related to Kaposi Sarcoma:

40
Skin, Endothelial, Lymph Node, Lung, T Cells, B Cells, Kidney

Publications for Kaposi Sarcoma

Articles related to Kaposi Sarcoma:

(show top 50) (show all 12970)
# Title Authors PMID Year
1
An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. 54 61 56 6
11001912 2000
2
HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. 61 56
22490805 2012
3
Salivary lactoferrin is recognized by the human herpesvirus-8. 61 56
15955101 2005
4
Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. 61 56
15220917 2004
5
Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. 61 56
15220918 2004
6
Epidemiology of classic Kaposi's sarcoma in the Israeli Jewish population between 1960 and 1998. 61 56
14583765 2003
7
Kaposi's sarcoma-associated herpesvirus--the high cost of viral survival. 61 56
13679522 2003
8
Expression of human herpesvirus 8 in primary pulmonary hypertension. 61 56
13679525 2003
9
Structure of an extracellular gp130 cytokine receptor signaling complex. 61 56
11251120 2001
10
High incidence of classical Kaposi's sarcoma in Iceland and the Faroe Islands. 61 56
9569061 1998
11
Monoclonal origin of multicentric Kaposi's sarcoma lesions. 61 56
9077377 1997
12
The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. 61 56
8705863 1996
13
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. 61 56
8705864 1996
14
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. 61 56
7997879 1994
15
An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. 61 56
6975437 1981
16
Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. 61 56
6272109 1981
17
Opportunistic infections and Kaposi's sarcoma in homosexual men. 61 56
6272112 1981
18
Kaposi's sarcoma. Retrospective study of 90 cases with particular emphasis on the familial occurrence, ethnic background and prevalence of other diseases. 61 56
7304649 1981
19
Familial Kaposi's sarcoma. 61 56
435392 1979
20
Kaposi's sarcoma in a father and son. 61 56
13788156 1960
21
Selected genes of Human herpesvirus-8 associated Kaposi's sarcoma among patients with Human Immunodeficiency Virus-1 and Acquired Immunodeficiency Disease Syndrome. 61 42
31404285 2019
22
Cloning a human saliva-derived peptide for preventing KSHV transmission. 56
22377758 2012
23
Interleukin-6 genetic variability and adiposity: associations in two prospective cohorts and systematic review in 26,944 individuals. 6
17623760 2007
24
Interleukin-6 involvement in brain arteriovenous malformations. 6
16278864 2006
25
Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. 6
16150725 2005
26
Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations. 6
15331795 2004
27
Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. 6
15472205 2004
28
Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. 6
15070960 2004
29
Association of a functional 17beta-estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females. 6
12719374 2003
30
The interleukin 6-174G/C polymorphism is associated with indices of obesity in men. 6
12560873 2003
31
Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. 6
12519862 2003
32
The -597 G-->A and -174 G-->C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. 6
11889177 2002
33
Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. 6
10720087 2000
34
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. 6
9769329 1998
35
Ultrasonography and magnetic resonance imaging features of kaposiform hemangioendothelioma and tufted angioma. 42
31373042 2019
36
Tacrolimus ointment for the treatment of superficial kaposiform hemangioendothelioma and tufted angioma. 42
31373046 2019
37
Complex N-linked glycans on Asn-89 of Kaposi sarcoma herpes virus-encoded interleukin-6 mediate optimal function by affecting cytokine protein conformation. 54 61
19690161 2009
38
Intralesional interferon alpha-2b therapy for adnexal Kaposi sarcoma. 54 61
19654515 2009
39
Linear IgA bullous dermatosis induced by interferon-alpha 2a. 54 61
19508467 2009
40
Kaposi's sarcoma-associated herpesvirus-G protein-coupled receptor-expressing endothelial cells exhibit reduced migration and stimulated chemotaxis by chemokine inverse agonists. 54 61
19258523 2009
41
ID2-VEGF-related pathways in the pathogenesis of Kaposi's sarcoma: a link disrupted by rapamycin. 54 61
19260835 2009
42
The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. 54 61
18836096 2009
43
Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells. 54 61
18566614 2008
44
The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. 54 61
18758494 2008
45
Sirolimus (rapamycin): from the soil of Easter Island to a bright future. 54 61
17583372 2007
46
Sulfated polymannuroguluronate, a novel anti-AIDS drug candidate, inhibits HIV-1 Tat-induced angiogenesis in Kaposi's sarcoma cells. 54 61
17868650 2007
47
AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa? 54 61
17656146 2007
48
Cytokine pattern in Kaposi's sarcoma associated with immune restoration disease in HIV and tuberculosis co-infected patients. 54 61
17721110 2007
49
Durable remission of HIV-negative, Kaposi's sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate. 54 61
16572284 2007
50
Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not". 54 61
17386117 2007

Variations for Kaposi Sarcoma

ClinVar genetic disease variations for Kaposi Sarcoma:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IL6 IL6, -174G-CSNV risk factor 14718

Cosmic variations for Kaposi Sarcoma:

9 (show top 50) (show all 60)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM93992510 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 9
2 COSM93451505 RAC1 soft tissue,lung,sarcoma,NS c.533C>T p.A178V 7:6402343-6402343 9
3 COSM101931022 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 9
4 COSM90842465 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 9
5 COSM87210160 PIK3CA soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 9
6 COSM101270110 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 9
7 COSM98770048 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 9
8 COSM97107943 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 1:114716123-114716123 9
9 COSM87804075 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 9
10 COSM87804055 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 9
11 COSM87850803 HGF soft tissue,lung,sarcoma,NS c.1711G>T p.V571L 7:81706333-81706333 9
12 COSM100583919 GPS2 soft tissue,lung,sarcoma,NS c.454C>T p.Q152* 17:7313932-7313932 9
13 COSM142908710 FOXP1 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 9
14 COSM100233796 ERCC2 soft tissue,lung,sarcoma,NS c.1831+1G>T p.? 19:45353082-45353082 9
15 COSM117948203 soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 9
16 COSM106841030 soft tissue,lung,sarcoma,NS c.2468T>G p.F823C 9:95458260-95458260 9
17 COSM118450453 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 9
18 COSM134990158 soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 9
19 COSM120158796 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 9
20 COSM143854306 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 9
21 COSM116715747 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 9
22 COSM103461667 soft tissue,lung,sarcoma,NS c.2468T>G p.F823C 9:95458260-95458260 9
23 COSM91788538 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 9
24 COSM102558626 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 9
25 COSM132326062 soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 9
26 COSM110727009 soft tissue,lung,sarcoma,NS c.2723T>G p.F908C 9:95458260-95458260 9
27 COSM134990190 soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 9
28 COSM93619977 soft tissue,lung,sarcoma,NS c.2738G>A p.R913H 3:52589201-52589201 9
29 COSM91028178 soft tissue,lung,sarcoma,NS c.2942C>T p.A981V 9:8404587-8404587 9
30 COSM91859752 soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 9
31 COSM98743623 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 9
32 COSM100223095 soft tissue,lung,sarcoma,NS c.1597+1G>T p.? 19:45353082-45353082 9
33 COSM134615012 soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 9
34 COSM89028226 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 9
35 COSM134614978 soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 9
36 COSM88073526 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 9
37 COSM89060405 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 9
38 COSM132607215 soft tissue,lung,sarcoma,NS c.2912C>T p.A971V 9:8404587-8404587 9
39 COSM108525670 soft tissue,lung,sarcoma,NS c.2723T>G p.F908C 9:95458260-95458260 9
40 COSM92729038 soft tissue,lung,sarcoma,NS c.476C>T p.A159V 7:6402343-6402343 9
41 COSM119483126 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 9
42 COSM91859771 soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 9
43 COSM102926575 soft tissue,lung,sarcoma,NS c.2879G>A p.R960H 3:52589201-52589201 9
44 COSM149000769 soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 9
45 COSM102156539 soft tissue,lung,sarcoma,NS c.2930C>T p.A977V 9:8404587-8404587 9
46 COSM91962426 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 9
47 COSM104534913 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 9
48 COSM102254463 soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 9
49 COSM113328424 soft tissue,lung,sarcoma,NS c.1696G>T p.V566L 7:81706333-81706333 9
50 COSM92957889 soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 9

Expression for Kaposi Sarcoma

Search GEO for disease gene expression data for Kaposi Sarcoma.

Pathways for Kaposi Sarcoma

Pathways related to Kaposi Sarcoma according to KEGG:

36
# Name Kegg Source Accession
1 Kaposi sarcoma-associated herpesvirus infection hsa05167
2 Viral carcinogenesis hsa05203

Pathways related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 VEGFA TP53 PDGFB IRF3 IL6ST IL6
2
Show member pathways
13.85 VEGFA TP53 PDGFB KDR IL6 FGF4
3
Show member pathways
13.71 TP53 KDR IL6ST IL6 IFNB1 IFNA2
4
Show member pathways
13.55 VEGFA TP53 PDGFB KDR IL6 IFNB1
5
Show member pathways
13.44 TP53 PDGFB KDR IL6 FGF4 FGF2
6
Show member pathways
13.34 VEGFA TP53 PDGFB IRF3 IFNB1 IFNA2
7
Show member pathways
13.33 PDGFB KDR IL6 FGF4 FGF2 CXCL1
8
Show member pathways
13.3 VEGFA PDGFB KDR IL6 FGF4 FGF2
9
Show member pathways
13.24 VEGFA TP53 PDGFB IRF3 IL6ST IL6
10
Show member pathways
13.16 TP53 IRF3 IL6 IFNB1 IFNA2 IFNA1
11
Show member pathways
13.09 TP53 PDGFB KDR IL6 FGF4 FGF2
12
Show member pathways
12.89 VEGFA IL6 IFNA2 IFNA1 ICAM1 CASP8
13 12.81 VEGFA TP53 PDGFB KDR FGF4 FGF2
14
Show member pathways
12.8 IRF3 IL6 IFNB1 IFNA2 IFNA1 CASP8
15
Show member pathways
12.79 TP53 IRF3 IL6 IFNB1 IFNA2 IFNA1
16
Show member pathways
12.76 VEGFA PDGFB KDR FGF4 FGF2
17
Show member pathways
12.73 PDGFB KDR IL6 FGF4 FGF2
18 12.72 VEGFA TP53 PDGFB IL6ST IL6 IFNA2
19 12.71 ZNF426 TP53 IRF3 IL6 IFNB1 IFNA2
20
Show member pathways
12.7 TP53 PDGFB FGF4 FGF2 CDK6
21
Show member pathways
12.67 VEGFA TP53 PDGFB KDR IL6 FGF2
22
Show member pathways
12.62 TP53 PDGFB IL6 FGF2 CXCL1
23
Show member pathways
12.6 VEGFA TP53 PDGFB KDR IRF3 IL6
24
Show member pathways
12.57 IRF3 IFNB1 IFNA2 IFNA1 ICAM1
25
Show member pathways
12.43 PDGFB KDR IL6 FGF4 FGF2
26
Show member pathways
12.42 VEGFA KDR FGF4 FGF2
27
Show member pathways
12.37 PDGFB IL6ST IL6 IFNB1 IFNA2 IFNA1
28
Show member pathways
12.36 IL6ST IL6 CXCL1 CASP8
29
Show member pathways
12.36 IL6ST IL6 CXCL1 CCR8
30 12.34 TP53 IRF3 IL6ST CDK6 CCR8 CASP8
31
Show member pathways
12.33 TP53 IRF3 IL6 FGF2
32 12.33 VEGFA TP53 KDR FGF2
33
Show member pathways
12.32 IL6 IFNB1 IFNA2 IFNA1
34 12.29 IL6 IFNB1 IFNA2 IFNA1 CASP8
35
Show member pathways
12.29 VEGFA TP53 PDGFB IRF3 IL6ST IL6
36
Show member pathways
12.24 IFNB1 IFNA2 IFNA1 CASP8
37 12.22 TP53 IRF3 IFNB1 IFNA2 IFNA1
38 12.21 IRF3 IL6 IFNB1 IFNA2 IFNA1 CXCL1
39 12.15 VEGFA TP53 PDGFB KDR ICAM1
40 12.11 VEGFA PDGFB KDR IL6 FGF4 FGF2
41 12.06 TP53 IL6 ICAM1 CXCL1
42
Show member pathways
12.06 TP53 PDGFB KDR IRF3 IL6 IFNB1
43 12.05 VEGFA TP53 IL6 ICAM1 FGF2
44 12.03 IL6 IFNB1 ICAM1 CXCL1 CASP8
45 11.99 TP53 IL6ST IL6 IFNB1 CXCL1
46 11.96 IL6ST IL6 IFNB1 IFNA2 IFNA1
47 11.92 VEGFA IL6 ICAM1 CXCL1
48
Show member pathways
11.92 IL6ST IL6 ICAM1 CXCL1
49 11.85 VEGFA PDGFB FGF4 FGF2
50 11.82 TP53 IL6 ICAM1

GO Terms for Kaposi Sarcoma

Cellular components related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 VEGFA PDGFB IL6 IFNB1 IFNA2 IFNA1
2 extracellular region GO:0005576 9.4 VEGFA PDGFB KDR IL6ST IL6 IFNB1
3 interleukin-6 receptor complex GO:0005896 9.16 IL6ST IL6

Biological processes related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.27 VEGFA PDGFB IL6ST IL6 IFNA1 FGF4
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.22 VEGFA TP53 IRF3 IL6 IFNB1 FGF4
3 multicellular organism development GO:0007275 10.21 VEGFA TP53 PDGFB KDR FGF4 FGF2
4 positive regulation of transcription, DNA-templated GO:0045893 10.11 TP53 PDGFB IRF3 IL6 IFNA2 FGF2
5 negative regulation of apoptotic process GO:0043066 10.08 VEGFA TP53 KDR IL6ST IL6 FGF4
6 positive regulation of gene expression GO:0010628 10.06 VEGFA TP53 PDGFB IL6 FGF4 CDK6
7 negative regulation of gene expression GO:0010629 9.99 VEGFA TP53 PDGFB KDR IFNA2
8 extracellular matrix organization GO:0030198 9.98 PDGFB KDR ICAM1 FGF2
9 positive regulation of cell proliferation GO:0008284 9.98 VEGFA PDGFB KDR IL6ST IL6 FGF4
10 cellular response to lipopolysaccharide GO:0071222 9.96 IRF3 IL6 ICAM1 CXCL1
11 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 PDGFB KDR ICAM1 FGF4 FGF2
12 defense response GO:0006952 9.93 IFNB1 IFNA2 IFNA1 CXCL1
13 defense response to virus GO:0051607 9.91 IRF3 IL6 IFNB1 IFNA2 IFNA1
14 B cell differentiation GO:0030183 9.86 IFNB1 IFNA2 IFNA1
15 interferon-gamma-mediated signaling pathway GO:0060333 9.85 TP53 IRF3 ICAM1
16 positive regulation of MAP kinase activity GO:0043406 9.85 VEGFA PDGFB FGF2
17 positive chemotaxis GO:0050918 9.82 VEGFA PDGFB FGF2
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 VEGFA IL6ST IL6 IFNA2
19 viral process GO:0016032 9.8 TP53 KDR IRF3 IL6ST ICAM1 CASP8
20 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.79 VEGFA KDR FGF2
21 B cell proliferation GO:0042100 9.79 IFNB1 IFNA2 IFNA1
22 positive regulation of endothelial cell proliferation GO:0001938 9.78 VEGFA PDGFB KDR FGF2
23 type I interferon signaling pathway GO:0060337 9.76 IRF3 IFNB1 IFNA2 IFNA1
24 T cell activation involved in immune response GO:0002286 9.74 IFNB1 IFNA2 IFNA1
25 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.73 IFNB1 IFNA2 IFNA1
26 cell migration involved in sprouting angiogenesis GO:0002042 9.71 VEGFA KDR FGF2
27 humoral immune response GO:0006959 9.71 IL6 IFNB1 IFNA2 IFNA1
28 natural killer cell activation involved in immune response GO:0002323 9.7 IFNB1 IFNA2 IFNA1
29 positive regulation of positive chemotaxis GO:0050927 9.68 VEGFA KDR
30 positive regulation of blood vessel endothelial cell migration GO:0043536 9.67 VEGFA PDGFB KDR FGF2
31 negative regulation of T cell differentiation GO:0045581 9.66 IFNB1 IFNA2
32 paracrine signaling GO:0038001 9.66 PDGFB FGF2
33 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.65 VEGFA TP53
34 chondroblast differentiation GO:0060591 9.64 FGF4 FGF2
35 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.64 VEGFA KDR
36 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.62 IFNB1 IFNA2
37 positive regulation of cell division GO:0051781 9.62 VEGFA PDGFB FGF4 FGF2
38 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000544 9.6 FGF4 FGF2
39 response to exogenous dsRNA GO:0043330 9.46 IRF3 IFNB1 IFNA2 IFNA1
40 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.35 VEGFA TP53 PDGFB IL6 ICAM1
41 cytokine-mediated signaling pathway GO:0019221 9.32 VEGFA TP53 IL6ST IL6 IFNB1 IFNA2

Molecular functions related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.98 VEGFA TP53 PDGFB KDR IRF3 IL6ST
2 protein homodimerization activity GO:0042803 9.93 VEGFA TP53 PDGFB IRF3 IL6ST ADA2
3 heparin binding GO:0008201 9.67 VEGFA FGF4 FGF2 ADA2
4 chemoattractant activity GO:0042056 9.5 VEGFA PDGFB FGF2
5 cytokine activity GO:0005125 9.5 VEGFA IL6 IFNB1 IFNA2 IFNA1 FGF2
6 cytokine receptor binding GO:0005126 9.43 IFNB1 IFNA2 IFNA1
7 interleukin-6 receptor binding GO:0005138 9.4 IL6ST IL6
8 type I interferon receptor binding GO:0005132 9.33 IFNB1 IFNA2 IFNA1
9 growth factor activity GO:0008083 9.17 VEGFA PDGFB IL6 FGF4 FGF2 CXCL1

Sources for Kaposi Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....